Agios Pharmaceuticals Inc... (AGIO)
33.88
-0.14 (-0.41%)
At close: Feb 20, 2025, 3:59 PM
33.75
-0.38%
After-hours: Feb 20, 2025, 04:00 PM EST
undefined% (undefined)
| Bid | 33.5 |
| Market Cap | 1.94B |
| Revenue (ttm) | - |
| Net Income (ttm) | - |
| EPS (ttm) | 11.64 |
| PE Ratio (ttm) | 2.91 |
| Forward PE | n/a |
| Analyst | Buy |
| Ask | 35.57 |
| Volume | 254,036 |
| Avg. Volume (20D) | 867,947 |
| Open | 34.00 |
| Previous Close | 34.02 |
| Day's Range | 33.25 - 33.93 |
| 52-Week Range | 26.66 - 62.58 |
| Beta | undefined |
About AGIO
Agios Pharmaceuticals, Inc., a biopharmaceutical company, engages in the discovery and development of medicines in the field of cellular metabolism and adjacent areas of biology. The company offers PYRUKYND (mitapivat) an activator of both wild-type and a variety of mutant pyruvate kinase, PK, enzymes for the treatment of hemolytic anemias; and AG-946 that is in Phase I clinical study for treating hemolytic anemias and other indications. Agios Ph...
Industry Biotechnology
Sector Healthcare
IPO Date Jul 24, 2013
Employees 486
Stock Exchange NASDAQ
Ticker Symbol AGIO
Website https://www.agios.com
Analyst Forecast
According to 8 analyst ratings, the average rating for AGIO stock is "Buy." The 12-month stock price forecast is $54, which is an increase of 59.39% from the latest price.
Buy 50.00%
Hold 37.50%
Sell 0.00%
3 months ago
-4.04%
Agios Pharmaceuticals shares are trading lower aft...
Unlock content with
Pro Subscription
4 months ago
-5.08%
Agios Pharmaceuticals shares are trading lower after Leerink Partners downgraded the stock from Outperform to Market Perform and cut its price target on the stock from $60 to $56.
